ORPHA:324636
Autoerythrocyte sensitization syndrome
Also known as: GDS · Gardner-Diamond syndrome · Painful bruising syndrome · Psychogenic purpura
Publications
256
64.7th percentile
Trials
0
Interventional, condition-specific
Researchers
698
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare autoimmune disease with skin involvement characterized by recurrent episodes with isolated or multiple painful edematous inflammatory skin lesions progressing to ecchymoses within 24 hours, due to autosensitization to a stromal component of the patient's own erythrocytes. The development of the lesions is usually preceded by emotional or physical stress, followed by a prodromal stage with fatigue or malaise. Lower limbs and trunk are the most frequently involved sites. Accompanying features may include fever, arthralgia, myalgia, headache, gastrointestinal problems, or hematuria and epistaxis, among others. The disease occurs predominantly in women.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017943
- MeSH:C535645
- UMLS:C0301928
Additional Mondo synonyms (2)
painful bruising syndrome · psychogenic purpura
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
256 matched papers (90 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
256
256 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
256 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
90 in the last 10 years · medium confidence · 64.7th percentile (publications denominator)
Phrase hits: 256 · MeSH hits: 4
Who's working on it?
698
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Jafferany M5 papers · 2025
Division of Child and Adolescent Psychiatry, University of Washington School of Medicine, Children's Hospital and Regional Medical Center, Seattle, WA, USA. mohammad.jafferany@seattlechildrens.org
Papers in Europe PMC - 02Hersle K3 papers · 1969Papers in Europe PMC
- 03Jerajani HR3 papers · 2013
Department of Dermatology, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai - 400022, India.
Papers in Europe PMC - 04Mobacken H3 papers · 1969Papers in Europe PMC
- 05Sarkar S3 papers · 2022
Department of Psychiatry, Calcutta National Medical College, Kolkata, West Bengal, India.
Papers in Europe PMC - 06Aktan M2 papers · 2010Papers in Europe PMC
- 07Bose S2 papers · 2025
Department of Dermatology, Venereology and Leprosy, City Hospital, Ernakulam, Kerala, India.
Papers in Europe PMC - 08Chiriac A2 papers · 2015
Department of Dermatology, Nicolina Medical Center, Iaşi, Romania.
Papers in Europe PMC - 09Ferizi M2 papers · 2019
Department of Dermatology, University Clinical Center of Kosovo, Prishtina, Kosovo.
Papers in Europe PMC - 10Foia L2 papers · 2015
Surgical Department, Grigore T Popa University of Medicine and Pharmacy, Iaşi, Romania.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Autoerythrocyte sensitization syndrome" OR "Gardner-Diamond syndrome" OR "Painful bruising syndrome" OR "Psychogenic purpura"
MeSH descriptor terms unioned into the query: Gardner-Diamond syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autoerythrocyte sensitization syndrome" OR "Gardner-Diamond syndrome" OR "Painful bruising syndrome" OR "Psychogenic purpura"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: GDS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:39:34.836Z